Page last updated: 2024-09-03

caprylates and 3,4-dihydroxyphenylacetic acid

caprylates has been researched along with 3,4-dihydroxyphenylacetic acid in 4 studies

Compound Research Comparison

Studies
(caprylates)
Trials
(caprylates)
Recent Studies (post-2010)
(caprylates)
Studies
(3,4-dihydroxyphenylacetic acid)
Trials
(3,4-dihydroxyphenylacetic acid)
Recent Studies (post-2010) (3,4-dihydroxyphenylacetic acid)
5,0611002,3395,41038591

Protein Interaction Comparison

ProteinTaxonomycaprylates (IC50)3,4-dihydroxyphenylacetic acid (IC50)
intestinal alkaline phosphatase precursorMus musculus (house mouse)4.17

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Araki, T; Imai, Y; Itoyama, Y; Kato, H; Takahashi, A1
Araki, T; Kato, H; Kurosaki, R; Oki, C1
Araki, T; Himeda, T; Kadoguchi, N; Kamiyama, Y; Kato, H; Maegawa, H1
Joniec-Maciejak, I; Maciejak, P; Mirowska-Guzel, D; Płaźnik, A; Sobolewska, A; Szyndler, J; Turzyńska, D; Wawer, A1

Other Studies

4 other study(ies) available for caprylates and 3,4-dihydroxyphenylacetic acid

ArticleYear
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
    Journal of the neurological sciences, 2003, Apr-15, Volume: 208, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2003
Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
    Brain research, 2004, Dec-24, Volume: 1030, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Cell Communication; Dopamine; Glial Fibrillary Acidic Protein; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Microglia; Movement Disorders; MPTP Poisoning; Neurons; Neuroprotective Agents; S100 Proteins

2004
Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
    Neuropharmacology, 2006, Volume: 50, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain; Brain Chemistry; Caprylates; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Homovanillic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Models, Biological; Motor Activity; Neuroprotective Agents; Neurotoxins; Nitric Oxide; Nitric Oxide Synthase; Superoxide Dismutase; Time Factors; Tyrosine 3-Monooxygenase

2006
Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caprylates; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; Neuroprotective Agents; Parkinson Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphoenolpyruvate Carboxykinase (GTP)

2018